2025 United States Alzheimer'S Disease Diagnostic Market Revenue Opportunities Report
Description
The 2025 United States Alzheimer'S Disease Diagnostic Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Alzheimer's Disease Diagnostic Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. Alzheimer's Disease Diagnostic Market include ALZpath, GE HealthCare, Quanterix Corporation, and Lantheus Holdings. ALZpath is recognized for its innovative blood-based pTau217 antibody allowing early, sensitive detection of Alzheimer's biomarkers and partners with major firms like Roche and Beckman Coulter for diagnostic assay development. GE HealthCare offers advanced PET and MRI imaging systems widely used to detect hallmark amyloid plaques and tau tangles, crucial in diagnosis and monitoring. Quanterix Corporation provides ultra-sensitive blood tests via its Simoa platform, enabling early Alzheimer's diagnosis with collaborations expanding its clinical reach. Lantheus Holdings focuses on F18-labeled tau PET radiodiagnostics (MK-6240), with successful pivotal study outcomes supporting its diagnostic sensitivity and specificity.
These companies benefit from the U.S.’s large Alzheimer's population (6.7 million affected as of 2024) and growing demand for early and accurate diagnostics driven by rising regulatory approvals and technological advances. The market emphasizes non-invasive, blood-based assays and advanced imaging, facilitating early detection, treatment monitoring, and clinical research. Academic and research institutions form a core segment collaborating closely with these companies to develop biomarkers and validation studies, further accelerating innovation and clinical adoption in the U.S..
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Alzheimer's Disease Diagnostic Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. Alzheimer's Disease Diagnostic Market include ALZpath, GE HealthCare, Quanterix Corporation, and Lantheus Holdings. ALZpath is recognized for its innovative blood-based pTau217 antibody allowing early, sensitive detection of Alzheimer's biomarkers and partners with major firms like Roche and Beckman Coulter for diagnostic assay development. GE HealthCare offers advanced PET and MRI imaging systems widely used to detect hallmark amyloid plaques and tau tangles, crucial in diagnosis and monitoring. Quanterix Corporation provides ultra-sensitive blood tests via its Simoa platform, enabling early Alzheimer's diagnosis with collaborations expanding its clinical reach. Lantheus Holdings focuses on F18-labeled tau PET radiodiagnostics (MK-6240), with successful pivotal study outcomes supporting its diagnostic sensitivity and specificity.
These companies benefit from the U.S.’s large Alzheimer's population (6.7 million affected as of 2024) and growing demand for early and accurate diagnostics driven by rising regulatory approvals and technological advances. The market emphasizes non-invasive, blood-based assays and advanced imaging, facilitating early detection, treatment monitoring, and clinical research. Academic and research institutions form a core segment collaborating closely with these companies to develop biomarkers and validation studies, further accelerating innovation and clinical adoption in the U.S..
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
